These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37243702)

  • 1. METTL3-mediated m
    Zhou Z; Cao Y; Yang Y; Wang S; Chen F
    Epigenetics; 2023 Dec; 18(1):2217033. PubMed ID: 37243702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer.
    Zhou S; Sheng L; Zhang L; Zhang J; Wang L
    Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130542. PubMed ID: 38103759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
    Pan X; Hong X; Li S; Meng P; Xiao F
    Exp Mol Med; 2021 Jan; 53(1):91-102. PubMed ID: 33420414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.
    Li S; Jiang F; Chen F; Deng Y; Pan X
    J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
    J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p.
    Sun H; Sun Y; Chen Q; Xu Z
    Life Sci; 2020 Jan; 241():117161. PubMed ID: 31837329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
    Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
    Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCNQ1OT1 affects cell proliferation, invasion, and migration through a miR-34a / Notch3 axis in breast cancer.
    Ren Z; Xu Y; Wang X; Ren M
    Environ Sci Pollut Res Int; 2022 Apr; 29(19):28480-28494. PubMed ID: 34993814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosome-Derived MicroRNA-221-3p Desensitizes Breast Cancer Cells to Adriamycin by Regulating
    Hong X; Pan X
    Cancer Biother Radiopharm; 2024 Aug; 39(6):463-475. PubMed ID: 38529940
    [No Abstract]   [Full Text] [Related]  

  • 10. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
    Lu Q; Chen W; Ji Y; Liu Y; Xue X
    Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
    [No Abstract]   [Full Text] [Related]  

  • 12. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p.
    Yue X; Wu WY; Dong M; Guo M
    Biomed J; 2021 Dec; 44(6 Suppl 2):S296-S304. PubMed ID: 35410813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP.
    Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y
    Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis.
    Zhai D; Zhou Y; Kuang X; Shao F; Zhen T; Lin Y; Wang Q; Shao N
    Int J Med Sci; 2023; 20(9):1152-1162. PubMed ID: 37575267
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
    Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
    J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined doxorubicin and arctigenin treatment induce cell cycle arrest-associated cell death by promoting doxorubicin uptake in doxorubicin-resistant breast cancer cells.
    Lee MG; Lee KS; Nam KS
    IUBMB Life; 2023 Sep; 75(9):765-777. PubMed ID: 37492896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
    Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
    Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsa_circ_0092276 promotes doxorubicin resistance in breast cancer cells by regulating autophagy via miR-348/ATG7 axis.
    Wang Q; Liang D; Shen P; Yu Y; Yan Y; You W
    Transl Oncol; 2021 Aug; 14(8):101045. PubMed ID: 34023560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.